The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.
Happify is making its app-based treatment available to patients thanks to a loosened FDA guidance last year that lets digital health companies targeting some behavioral health conditions release their product without clearance. The company is launching an investigational study to get data for a future FDA submission.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
A Sage Therapeutics depression drug that failed a pivotal study in 2019 has positive preliminary results from a new Phase 3 clinical trial, but the data also showed the therapy's effects waned over time. Questions about zuranolone’s durability are relevant to Biogen, which committed $1.5 billion to Sage in large part due to the drug’s potential in multiple psychiatric indications.
Healthcare staff are working through immense loss, grief and uncertainty to provide care during the Covid-19 pandemic. As organizations think about how to support their staff, speakers at a MedCity INVEST panel said they must first talk about it openly and provide a safe space for workers to discuss their feelings.
It may seem intuitive to avoid telehealth or remote care to avoid increased liability and malpractice exposure. But remote behavioral health assessment tools, real-time data-driven insights, and adaptive treatment plans are actually the things that protect clinicians from civil liability in instances of patient suicide.
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The Pennsylvania-based insurer is offering members using its small group products access to the NeuroFlow app, which provides self-guided activities to combat mental health issues.
The Covid mental health crisis curve stands to cataclysmically increase the number of deaths associated with the pandemic.
Alphabet’s “moonshot” subsidiary X shared that it failed to find a single biomarker for depression and anxiety. But the company still plans to make its research, which included developing portable EEGs, available to the public.
The Administration for Community Living, part of the Department of Health and Human Services, is taking steps to establish a National Volunteer Care Corps.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Salt Lake City-based Myriad Genetics' GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression.
The company's cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient's forehead.
Based on the literature review conducted by the researchers, only 14 percent of top ranked behavioral health apps described design or development that was based on real-world evidence.
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
The drug, a reformulation of ketamine, was approved for patients who have failed on other antidepressants. The original form of ketamine, approved as an anesthetic, has long been explored as a treatment for depression.